Panel of mRNA biomarkers for pancreatic cancer (mRNA-PDAC Panel)

A panel of mRNA biomarkers for pancreatic cancer refers to a coordinated set of messenger RNA transcripts whose expression levels are measured collectively to detect, stage, or predict the prognosis of pancreatic ductal adenocarcinoma (PDAC). These panels are often developed for use in liquid biopsies (blood or saliva) or tissue samples to identify molecular signatures that distinguish malignant cells from healthy tissue or chronic pancreatitis (Source: Scientific Reports, 2020, PMID: 32855462). Common genes included in such panels often involve those related to cell cycle regulation, epithelial-mesenchymal transition, and mucin production, such as KRT19, MUC1, and BIRC5 (Source: PubMed, PMC7452915). While the individual mRNA components represent proteins that may be therapeutic targets, the panel itself is a diagnostic tool rather than a direct target for drug intervention. The clinical utility of these panels lies in their ability to provide higher diagnostic accuracy than single-marker assays like CA 19-9, particularly for early-stage detection where surgical intervention is most effective. By leveraging transcriptomic data, these panels assist in patient stratification and the monitoring of therapeutic efficacy in a disease characterized by late-stage presentation and high mortality (Source: Journal of Clinical Oncology, 2021).

Other names

Pancreatic cancer gene expression signaturePDAC mRNA diagnostic panelTranscriptomic biomarker panel for pancreatic adenocarcinomaBlood-based mRNA signature for pancreatic cancer

Not applicable as this is a diagnostic biomarker panel rather than a therapeutic target. The panel functions by quantifying the relative abundance of specific mRNA transcripts to identify a molecular signature associated with malignancy.